Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.43 |
| ▸ | TLR4 | O00206 | 1/20 | 0.43 |
| ▸ | TLR2 | O60603 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21501382 | 0.88 | MEN1 (0.47) | KDM4ELMNAMMP1MMP13MMP2 | |
| SCHEMBL7916927 | 0.86 | KDM4E (0.46) | KDM4ELMNAMMP1MMP13MMP2 | |
| SCHEMBL21469684 | 0.83 | HTT (0.58) | KDM4ELMNAMMP1MMP13MMP2 | |
| SCHEMBL11143982 | 0.83 | PTGS2 (0.57) | KDM4ELMNAPTGS2LTA4HTLR4 | |
| SCHEMBL7981017 | 0.81 | SMN1; SMN2 (0.62) | KDM4ELMNAMMP1MMP13MMP2 | |
| SCHEMBL10753672 | 0.78 | PTGS2 (0.50) | KDM4ELMNAMMP1MMP13MMP2 | |
| SCHEMBL29604461 | 0.78 | L3MBTL1 (0.54) | KDM4EPTGS2LTA4HPOLBPDE10A | |
| SCHEMBL3985514 | 0.78 | L3MBTL1 (0.54) | KDM4EPTGS2LTA4HPOLBPDE10A | |
| SCHEMBL924384 | 0.78 | ADAMTS4 (0.56) | KDM4ELMNAMMP1MMP13MMP2 | |
| SCHEMBL9536733 | 0.77 | SOS1 (0.64) | KDM4ELMNAMMP1MMP13MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7868188-B2 | 5-heteroaryl thiazoles and their use as PI3K inhibitors | ASTRAZENECA AB (SE) | 2011-01-11 | — | — | US | disclosed |
| US-20100279986-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-11-04 | — | — | US | disclosed |
| US-7803793-B2 | Heterocyclic derived metalloprotease inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-28 | — | — | US | disclosed |
| EP-1841763-B1 | 5-HETEROARYL THIAZOLES AND THEIR USE AS PI3K INHIBITORS | ASTRAZENECA AB (SE) | 2010-06-30 | — | — | EP | disclosed |
| WO-2010039911-A1 | CALCILYTIC COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2010-04-08 | — | — | WO | disclosed |
| EP-2089365-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2009-08-19 | — | — | EP | disclosed |
| US-20080287466-A1 | 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ADAMS JERRY LEROY | 2008-11-20 | — | — | US | disclosed |
| US-7427623-B2 | 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-23 | — | — | US | disclosed |
| US-20080132502-A1 | 5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors | ASTRAZENECA AB (SE) | 2008-06-05 | — | — | US | disclosed |
| US-20080103129-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-05-01 | — | — | US | disclosed |
| US-20030130506-A1 | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation | AGOURON PHARMACEUTICALS, INC. (US) | 2003-07-10 | — | — | US | disclosed |
| WO-2003022852-A2 | FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-20 | — | — | WO | disclosed |
| US-6500948-B1 | SUCH AS N-HYDROXY-4-(4-((PYRID-4-YL)OXY)BENZENESULFONYL)-2,2-DIMETHYL-TETRAHYDRO-2H -1,4-THIAZINE-3-CARBOXYLIC ACID | AGOURON PHARMACEUTICALS, INC. | 2002-12-31 | — | — | US | disclosed |
| US-H1992-H1 | INHIBITION OF METALLOPROTEINASES AND TUMOR NECROSIS FACTOR CONVERTASE WHICH DEGRADE PROTEIN COMPONENTS OF EXTRACELLULAR MATRIX | AGOURON PHARMACEUTICALS, INC. | 2001-09-04 | — | — | US | disclosed |
| EP-1095936-A1 | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation | AGOURON PHARMACEUTICALS, INC. (US) | 2001-05-02 | — | — | EP | disclosed |
| US-6153757-A | A PRODRUG, SALT OR SOLVATE AS ANTITUMOR AGENT AND ENZYME INHIBITOR FOR INHIBITING METALLOPROTEINASES, TUMOR NECROSIS FACTOR | AGOURON PHARMACEUTICALS, INC. (US) | 2000-11-28 | — | — | US | disclosed |
| EP-0973748-A1 | METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES | AGOURON PHARMACEUTICALS, INC. (US) | 2000-01-26 | — | — | EP | disclosed |
| US-5985900-A | TREATING TUMOR GROWTH, INVASION OR METASTASIS, OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, OSTEOPOROSIS, PERIODONTITIS, GINGIVITIS, CHRONIC DERMAL WOUNDS, CORNEAL ULCERATION, DEGENERATIVE SKIN DISORDERS, MULTIPLE SCLEROSIS, STROKE, ATHEROSCLEROSIS, | AGOURON PHARMACEUTICALS, INC. (US) | 1999-11-16 | — | — | US | disclosed |
| WO-1998050348-A1 | METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES | AGOURON PHARMACEUTICALS, INC. (US) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998043963-A1 | METALLOPROTEINASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PHARMACEUTICAL USES | AGOURON PHARMACEUTICALS, INC. (US) | 1998-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130506-A1 | Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation | MMP9, MMP3, MMP2 | KDM4E 1395/4885LMNA 1257/4885MMP1 5/4885 |
| US-20080103129-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | ADAM17, MMP25, ADAM33 | KDM4E 1117/4885LMNA 1019/4885MMP1 15/4885 |
| US-20100279986-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | ADAM17, MMP25, ADAM33 | KDM4E 1117/4885LMNA 1019/4885MMP1 15/4885 |
| US-20080287466-A1 | 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | TIE1, TEK, KDR | KDM4E 202/4885LMNA 4131/4885MMP1 4258/4885 |
| US-20080132502-A1 | 5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors | MTOR, PIK3R5, PIK3CA | KDM4E 1979/4885LMNA 4256/4885MMP1 4216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.